Vape Additives that Mimic Nicotine Are Potentand Largely UnregulatedThe introduction of synthetic nicotine analogs in vaping products raises significant health concerns and regulatory challenges.
Revealed: ex-director for tobacco giant advising UK government on cancer risksA former PMI director's role on a UK cancer advisory committee raises concerns about conflicts of interest and potential influence on public health policy.
Wait, Is This the End of Cigarettes?The FDA proposes significantly reducing nicotine levels in cigarettes to curb addiction, potentially transforming smoking habits in America.
Experts condemn US tobacco firm's sponsorship of doctor training as grotesque'The tobacco company Philip Morris sponsoring medical education is seen as a strategy to influence medical practice and regain credibility, criticized by experts for undermining public health.
Pressure mounts on publisher of Economist over ties to tobaccoThe Economist is facing criticism for its connections with major tobacco companies, impacting health conferences.
Economist Group cancer conference cancelled due to links to tobacco firmsEconomist Impact canceled a cancer conference due to backlash over ties with tobacco companies, reflecting widespread disapproval in the health community.
Vape Additives that Mimic Nicotine Are Potentand Largely UnregulatedThe introduction of synthetic nicotine analogs in vaping products raises significant health concerns and regulatory challenges.
Revealed: ex-director for tobacco giant advising UK government on cancer risksA former PMI director's role on a UK cancer advisory committee raises concerns about conflicts of interest and potential influence on public health policy.
Wait, Is This the End of Cigarettes?The FDA proposes significantly reducing nicotine levels in cigarettes to curb addiction, potentially transforming smoking habits in America.
Experts condemn US tobacco firm's sponsorship of doctor training as grotesque'The tobacco company Philip Morris sponsoring medical education is seen as a strategy to influence medical practice and regain credibility, criticized by experts for undermining public health.
Pressure mounts on publisher of Economist over ties to tobaccoThe Economist is facing criticism for its connections with major tobacco companies, impacting health conferences.
Economist Group cancer conference cancelled due to links to tobacco firmsEconomist Impact canceled a cancer conference due to backlash over ties with tobacco companies, reflecting widespread disapproval in the health community.
Nicotine pouches are selling fast and falling into minors' handsPhilip Morris aims to achieve two-thirds of its revenue from smoke-free alternatives by 2030, amidst rising concerns about youth nicotine use.
Philip Morris sells asthma inhaler company, citing unwarranted opposition' to its goalsPhilip Morris International is divesting its asthma inhaler business, Vectura, due to skepticism surrounding its transformation from tobacco to health.
Nicotine pouches are selling fast and falling into minors' handsPhilip Morris aims to achieve two-thirds of its revenue from smoke-free alternatives by 2030, amidst rising concerns about youth nicotine use.
Philip Morris sells asthma inhaler company, citing unwarranted opposition' to its goalsPhilip Morris International is divesting its asthma inhaler business, Vectura, due to skepticism surrounding its transformation from tobacco to health.
No One Needs a Vape With a ScreenTobacco companies are introducing screen-equipped e-cigarettes that may make them more appealing and potentially addictive, particularly to youth.
Altria Tops Market Increase and Has 8.4% YieldAltria's stock performance has defied expectations, outperforming the market while also providing a substantial dividend to investors.
Marlboro is the world's most valuable tobacco brand - London Business News | Londonlovesbusiness.comGlobal top tobacco brands value down 6%, indicating a shift to smokeless products amid changing consumer preferences and regulatory pressures.
America's Best Dividend Stock Thrives In Market DownturnAltria's stock has risen 10% in the last month, with a 7.7% yield and consistent dividend increases for 54 years.